New antibody aims to calm ulcerative colitis when other treatments fail
Disease control
Completed
This phase 2 trial tests whether OSE-127, an antibody that blocks a key immune signal, can reduce disease activity in people with moderate to severe ulcerative colitis who have not responded to or cannot tolerate previous treatments. Participants are randomly assigned to receive …
Phase: PHASE2 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC